HeartFlow, Inc. is a personalized medical technology company seeking to transform the way coronary artery disease (CAD) is diagnosed and treated. The company’s HeartFlow FFRct Analysis is the first available non-invasive solution that enables a physician to more accurately evaluate whether a patient has significant CAD based on both anatomy and physiology. The solution leverages deep learning, an advanced form of artificial intelligence, to create a personalized 3D model of the patient’s arteries. It is well positioned to become an integral part of the standard of care for patients who are at risk for CAD because of its potential to improve clinical outcomes, improve the patient experience and reduce the cost of care. The HeartFlow FFRct Analysis is available in the United States, Canada, Europe and Japan.